Research to Remission Grant
The Research to Remission Grant is designed to provide funding for research that may lead to a significant change in the understanding, diagnosis, and/or treatment of multiple myeloma. Each year, CMRG, with the support of its partners, provides funding for myeloma research. We welcome applicants who hold a Ph.D., M.D., D.V.M, or equivalent and have a demonstrated research environment suitable for their proposed study. For 2021, CMRG will be accepting applications for Real-World Evidence Research using the CMRG Database.
Supported by a research grant from Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.
Thank you for your interest in the CMRG Research Grant. The application deadline this year has passed.
We thank all applicants for this proposals and congratulate Dr. Rayan Kaedbey on being the recipient of this year’s Research to Remission grant.
Study: Impact of maintenance therapy after salvage autologous stem cell transplantation in relapsed multiple myeloma